Emerging Molecules
Semaglutide is one molecule and at least two evidence files
SELECT used 2.4 mg weekly in people without diabetes. FLOW used 1 mg weekly in people…
Section
Emerging Molecules
Mechanisms and early trials that are still moving.
Emerging Molecules
Adding type 2 diabetes changes the tirzepatide weight percentage
SURMOUNT-2, in adults with obesity and type 2 diabetes, did not reproduce the weight change reported…
Emerging Molecules
Before the obesity trials, tirzepatide had to win a diabetes phase 2
Frias and colleagues tested LY3298176, the dual GIP and GLP-1 agonist later named tirzepatide, against placebo…
Emerging Molecules
CJC-1295 with DAC raised GH and IGF-I for days in healthy adults
Teichman 2006 and Ionescu 2006 describe the long-acting, Drug Affinity Complex form. “No DAC” is a…
Emerging Molecules
SS-31 is a cardiolipin-targeted peptide with a drug-development history
Szeto’s 2014 review describes a first-in-class mitochondrial peptide. Any approved use, if one exists when you…